-
公开(公告)号：EP4420663A3
公开(公告)日：2024-10-30
申请号：EP24173692.5
申请日：2014-12-19
发明人： BROGDON, Jennifer , ENGELS, Boris , GLASS, David Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , SELLERS, William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
IPC分类号： C07K19/00 , C12N5/0783 , A61K31/436 , A61K35/17 , C07K14/725 , C07K16/28
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号：EP4219721A3
公开(公告)日：2023-09-06
申请号：EP23151319.3
申请日：2017-04-14
发明人： GOLOSOV, Andrei , GUIMARAES, Carla , MOTZ, Gregory , MILONE, Michael , ELLEBRECHT, Christoph T. , PAYNE, Aimee S.
IPC分类号： C12N15/62 , C07K14/725
摘要： Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two.
Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer.
Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.-
公开(公告)号：EP3443096A2
公开(公告)日：2019-02-20
申请号：EP17737079.8
申请日：2017-04-14
发明人： GOLOSOV, Andrei , GUIMARAES, Carla , MOTZ, Gregory , MILONE, Michael , ELLEBRECHT, Christoph, T. , PAYNE, Aimee, S.
IPC分类号： C12N15/62 , C07K14/725
-
公开(公告)号：EP4420663A2
公开(公告)日：2024-08-28
申请号：EP24173692.5
申请日：2014-12-19
发明人： BROGDON, Jennifer , ENGELS, Boris , GLASS, David Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , SELLERS, William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
IPC分类号： A61K31/436
CPC分类号： C07K14/7051 , C07K14/70521 , C07K14/70539 , C07K14/70578 , C12N9/90 , C07K2319/0020130101 , C07K2319/0320130101 , C07K2319/7020130101 , C12N9/1205 , C07K2319/4120130101 , C07K2319/4320130101 , A61K31/436 , C12Y502/00 , A61P35/00 , A61P37/04 , A61K39/464468 , A61K2239/2420230501 , A61K2239/4820230501 , A61K39/4631 , A61K39/464404 , A61K2239/2320230501 , A61K39/4611 , A61K2239/3820230501 , A61K39/464412
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号：EP3183268B1
公开(公告)日：2020-02-12
申请号：EP15756525.0
申请日：2015-08-19
发明人： KENDERIAN, Saad , BROGDON, Jennifer , GILL, Saar , GLASS, David , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , PORTER, David L. , RUELLA, Marco , WANG, Yongqiang , WU, Qilong , ZHANG, Jiquan
IPC分类号： C07K16/28 , A61K39/395
-
公开(公告)号：EP3087101A1
公开(公告)日：2016-11-02
申请号：EP14872734.0
申请日：2014-12-19
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Brogdon, Jennifer , Engels, Boris , GLASS, David, Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , Milone, Michael C. , MURPHY, Leon , SELLERS, William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
发明人： BROGDON, Jennifer , ENGELS, Boris , GLASS, David Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , SELLERS,William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
IPC分类号： C07K19/00 , C12N5/0783
CPC分类号： C07K16/2863 , A61K31/436 , A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/41 , C07K2319/43 , C07K2319/70 , C12N9/1205 , C12N9/90 , C12Y502/00
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
摘要翻译： 提供了与可调节嵌合抗原受体（RCAR）相关的组合物和方法，其中可以控制RCAR的细胞内信号传导或增殖以优化使用表达RCAR的细胞以提供免疫应答。 例如，RCAR可以包含二聚转换开关，其在存在二聚化分子时可以将细胞内信号转导域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域或共刺激ECD结构域 。 RCAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。
-
公开(公告)号：EP4219721A2
公开(公告)日：2023-08-02
申请号：EP23151319.3
申请日：2017-04-14
发明人： GOLOSOV, Andrei , GUIMARAES, Carla , MOTZ, Gregory , MILONE, Michael , ELLEBRECHT, Christoph T. , PAYNE, Aimee S.
IPC分类号： C12N15/62 , C07K14/725
摘要： Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two.
Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer.
Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.-
公开(公告)号：EP3712171A1
公开(公告)日：2020-09-23
申请号：EP19219069.2
申请日：2015-08-19
发明人： KENDERIAN, Saad , BROGDON, Jennifer , GILL, Saar , GLASS, David , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , PORTER, David L , RUELLA, Marco , WANG, Yongqiang , WU, Qilong , ZHANG, Jiquan
IPC分类号： C07K16/28 , A61K39/395
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
-
9.发明公开ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR) FOR USE IN CANCER TREATMENT 审中-公开抗癌CD123嵌合抗原受体（CAR）用于癌症治疗
公开(公告)号：EP3183268A1
公开(公告)日：2017-06-28
申请号：EP15756525.0
申请日：2015-08-19
发明人： KENDERIAN, Saad , BROGDON, Jennifer , GILL, Saar , GLASS, David , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , PORTER, David L. , RUELLA, Marco , WANG, Yongqiang , WU, Qilong , ZHANG, Jiquan
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2866 , A61K39/0011 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , C07K16/244 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/03 , C07K2319/33 , C12N5/0636
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
摘要翻译： 本发明提供了用于治疗与CD123表达相关的疾病的组合物和方法。 本发明还涉及对CD123特异性的嵌合抗原受体（CAR），编码CD123的载体和包含CD123 CAR的重组细胞。 本发明还包括施用表达包含CD123结合结构域的CAR的基因修饰细胞的方法。
-
10.发明公开
公开(公告)号：EP3340995A1
公开(公告)日：2018-07-04
申请号：EP16842710.2
申请日：2016-08-26
CPC分类号： A61K35/17 , A61K35/00 , A61K35/12 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N5/0636
摘要： The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.042 秒)
